Early-demographic dividend vs Guyana: Immunization, Hib3
Early-demographic dividend
86.1%
in 2024
Guyana
98.0%
in 2024
Early-demographic dividend rank
17th
Guyana rank
20th
Immunization, Hib3 over time
- Early-demographic dividend
- Guyana
How they compare
Guyana currently reports 98.0% against 86.1% in Early-demographic dividend, a difference of 11.9%.
That makes Guyana's figure about 1.1 times Early-demographic dividend's.
Across all 24 years both countries report, Guyana has been ahead every year.
Early-demographic dividend ranks 17th and Guyana ranks 20th of 43 groups.
Guyana has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Early-demographic dividend | Guyana | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 15.5% | 92.0% | 76.5% | Guyana |
| 2010s | 61.9% | 96.4% | 34.5% | Guyana |
| 2020s | 84.4% | 98.2% | 13.8% | Guyana |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Early-demographic dividend or Guyana?
- Guyana, at 98.0% against 86.1% in Early-demographic dividend as of 2024.
- What is the difference in immunization, hib3 between Early-demographic dividend and Guyana?
- 11.9%, with Guyana ahead.
- How many years of comparable data are there for Early-demographic dividend and Guyana?
- 24 years are reported by both, from 2001 to 2024.
- How do Early-demographic dividend and Guyana rank globally for immunization, hib3?
- Early-demographic dividend ranks 17th and Guyana ranks 20th of 43 groups.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.